Date of Publication: 30-01-2026
INTELLIGENCE OVERVIEW
Agency: European Medicines Agency (EMA)
Product: AstraZeneca AB. – Imfinzi (Durvalumab)
Indication: Gastric or Gastro-oesophageal Junction Adenocarcinoma (GC/GEJC)
Status: Positive CHMP opinion
Industry Impact
This decision reflects key regulatory and market trends:
- Confirms EMA’s support for perioperative immuno-oncology strategies
- Strengthens lifecycle management opportunities for established oncology biologics
- Encourages sponsors to pursue label expansion into earlier disease settings
- Highlights the importance of robust combination-therapy evidence in post-authorisation variations
Overall, the opinion reinforces a regulatory environment that supports innovation beyond initial approvals, expanding patient access while extending product value across the EU.
https://www.ema.europa.eu/en/medicines/human/variation/imfinzi